Please take the chance to talk to InnoSer about InfiCure Bio ABs unique NIF mouse model at the 6th NASH Congress! The NIF model spontaneously develops chronic inflammation and fibrosis, which is nicely presented in Innosers poster.

InfiCure Bio has started 2023 by signing an agreement with a new client in the US. Read the whole pressrelease here

InfiCure Bio enjoyed a traditional Swedish Christmas lunch at beautiful Brännlands Wärdshus. It is hard to find a more Christmasy atmosphere- and the recent snow and cold weather added an extra touch.  We wish you all a wonderful Christmas holiday!

InnoSer and Inficure Bio enter partnership to increase accessibility of translational liver inflammation & fibrosis mouse model Read the entire pressrelease here!

The Umeå based life science company InfiCure Bio continues to take large steps in the global market by signing agreements with two major international companies. “The contracts with our new clients clearly show that pharmaceutical companies continue to invest in the development of new drugs for fibrosis, which is extremely promising for InfiCure Bio”, says [...]

Sofia Mayans, CEO at Inficure Bio, will attend the annual Nordic Life Science Days in Malmö 28-29 September. We hope that you will meet Sofia in Malmö for fruitful discussions!

InfiCure attended the EASL NAFLD summit digitally, please take the opportunity to read our poster  "Effects of high fat diet on development of NASH in the NIF mouse model". The poster can be found here.

InfiCure Bio presented the poster "NKT cells promote both type 1 and type 2 inflammatory responses in the non-obese diabetic inflammation and fibrosis (NIF) mouse model". You will find the poster here.

InfiCure Bio will attend the yearly EASL meeting with a poster, please take the opportunity to check out poster #FRI-154 "NKT cells promote both type 1 and type 2 inflammatory responses in the non-obese diabetic inflammation and fibrosis (NIF) mouse model".